Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Opko Health Inc (OPK)

Opko Health Inc (OPK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AngioDynamics Unveils Auryon Atherectomy System for PAD

AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.

ANGO : 10.12 (+2.02%)
SRDX : 38.28 (-0.83%)
MMSI : 41.84 (-0.29%)
OPK : 3.19 (-1.85%)
Accuray's Radixact With Synchrony Used in Japan Hospitals

The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.

ARAY : 2.50 (-4.21%)
SRDX : 38.28 (-0.83%)
MMSI : 41.84 (-0.29%)
OPK : 3.19 (-1.85%)
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 56.50 (+0.66%)
REGN : 569.74 (+2.53%)
AMGN : 246.61 (+1.41%)
IBB : 133.80 (+0.73%)
OPK : 3.19 (-1.85%)
XBI : 112.66 (+0.56%)
DexCom Introduces Registry to Monitor Outcomes of G6 System

DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.

DXCM : 392.49 (+0.20%)
SRDX : 38.28 (-0.83%)
MMSI : 41.84 (-0.29%)
OPK : 3.19 (-1.85%)
Here's Why You Should Retain Avanos Medical Stock for Now

Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.

SRDX : 38.28 (-0.83%)
MMSI : 41.84 (-0.29%)
OPK : 3.19 (-1.85%)
AVNS : 33.65 (+1.91%)
Diagnostic Devices Give the Healthcare System New Avenues for Innovation

, /PRNewswire/ -- The recent pandemic, which has put a heavy toll on our economy and pushed the healthcare system into a severe scarcity problem, further illustrates the importance of medical devices...

OPK : 3.19 (-1.85%)
NMRD : 3.62 (-0.82%)
IBIO : 2.27 (-6.58%)
CODX : 15.43 (+1.71%)
NVAX : 111.81 (+1.51%)
OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy

OPKO Health (OPK) is developing its marketed drug, Rayaldee, as a potential treatment for patients with mild-to-moderate COVID-19.

RHHBY : 46.3100 (+0.02%)
INCY : 86.25 (+1.01%)
LLY : 149.97 (-0.80%)
OPK : 3.19 (-1.85%)
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know

OPKO Health (OPK) closed at $3.15 in the latest trading session, marking a -0.63% move from the prior day.

OPK : 3.19 (-1.85%)
Here's Why You Should Add Surmodics to Your Portfolio Now

Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.

SRDX : 38.28 (-0.83%)
MMSI : 41.84 (-0.29%)
OPK : 3.19 (-1.85%)
NXGN : 12.24 (-1.84%)
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients

OPKO Health, Inc. (NASDAQ: OPK) announces the initiation of a Phase 2 trial with RAYALDEE as a treatment for mild-to-moderate COVID-19. The trial, "A Randomized, Double-Blind Placebo-Controlled Study...

OPK : 3.19 (-1.85%)
Unprecedented Global Events Lead Diagnostic Providers to Innovative Breakthroughs

, /PRNewswire/ -- As the pandemic continues to spread throughout the U.S., the need for testing is on the rise as well. Nevertheless, many states and regions are experiencing a shortage of tests, which...

TOMDF : 0.0940 (-0.21%)
AYTU : 1.2750 (-1.92%)
DVAX : 4.96 (-2.36%)
CODX : 15.43 (+1.71%)
PTE : 1.0600 (+0.95%)
OPK : 3.19 (-1.85%)
Here's Why You Should Retain Allscripts (MDRX) Stock for Now

Investor confidence is high on Allscripts (MDRX) stock, thanks to solid prospects.

MDRX : 7.87 (-0.76%)
SRDX : 38.28 (-0.83%)
MMSI : 41.84 (-0.29%)
OPK : 3.19 (-1.85%)
Is OPKO Health (OPK) Outperforming Other Medical Stocks This Year?

Is (OPK) Outperforming Other Medical Stocks This Year?

OPK : 3.19 (-1.85%)
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.

DVA : 84.84 (-0.33%)
SRDX : 38.28 (-0.83%)
MMSI : 41.84 (-0.29%)
OPK : 3.19 (-1.85%)
HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates

HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q2.

PKI : 119.76 (+1.28%)
TMO : 430.62 (+1.21%)
OPK : 3.19 (-1.85%)
HQY : 47.57 (-1.67%)
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.

CNMD : 75.63 (+3.19%)
SRDX : 38.28 (-0.83%)
MMSI : 41.84 (-0.29%)
OPK : 3.19 (-1.85%)
OPKO Health's BioReference Laboratories Introduces NGS Assay

OPKO Health's (OPK) OnkoSight Advanced is a NGS assay that facilitates revolutionary DNA mutational profiling of tumor samples.

SRDX : 38.28 (-0.83%)
MMSI : 41.84 (-0.29%)
OPK : 3.19 (-1.85%)
NXGN : 12.24 (-1.84%)
OPKO Health to Participate in Two September Investment Conferences

OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in two upcoming virtual investor conferences.

OPK : 3.19 (-1.85%)
Baxter (BAX) Attains FDA De Novo Authorization for Theranova

Baxter's (BAX) expanded HDx therapy delivered by Theranova becomes accessible for patients with kidney failure in the United States.

BAX : 79.21 (-1.30%)
SRDX : 38.28 (-0.83%)
MMSI : 41.84 (-0.29%)
OPK : 3.19 (-1.85%)
OPKO Health's BioReference Laboratories Announces New York City Schools COVID-19 Testing Program

, /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today began testing principals, teachers and other staff for COVID-19, across the five boroughs, in preparation...

OPK : 3.19 (-1.85%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar